Date:		_	5/26/2023			
Your Name:		_	Rebecca Spencer			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	nown):	169199-JCI-CMED-RV-2			
cor affo ind	ntent of your manuscri ected by the content o licate a bias. If you are e author's relationship	pt. "Rela of the man e in doubt s/activitie	ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For e	/interest, it is preferable that you do so.		
	it medication is not me			detailers of untillypertensive medication, even in		
	tem #1 below, report a			vithout time limit. For all other items, the time		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Europea (FP7/20 The Mit	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn	Chief Investigator Anna David, institutional payments Institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Europea (FP7/20 The Mit Shoshar Rosetre	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 Inchell Charitable Trust in memory of Ina Mitchell Glynn Inchell Glynn	Institutional payments Institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Europea (FP7/20 The Mit Shoshar Rosetre Nationa	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn	payments Institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europea (FP7/20 The Mit Shoshar Rosetre Nationa College	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn es Trust	Institutional payments Institutional payments Access to facilities for sample processing		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Europea (FP7/20) The Mit Shoshar Rosetre Nationa College Centre	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn es Trust ll Institute for Health Research University London Hospitals Biomedical Research Time frame: past 36 monthone	Institutional payments Institutional payments Access to facilities for sample processing		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europea (FP7/20 The Mit Shoshar Rosetre Nationa College Centre Note Academ 125944 Nationa	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn es Trust ll Institute for Health Research University London Hospitals Biomedical Research Time frame: past 36 monthone	Institutional payments Institutional payments Access to facilities for sample processing		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Europea (FP7/20 The Mit Shoshar Rosetre Nationa College Centre No Academ 125944 Nationa Clinical	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 chell Charitable Trust in memory of na Mitchell Glynn es Trust chell Glynn es Trust chell Institute for Health Research University London Hospitals Biomedical Research Time frame: past 36 month one ny of Medical Sciences starter grant chell Institute for Health and Care Research	Institutional payments Institutional payments Access to facilities for sample processing Payment to institution		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	□ None National Institute for Health and Care Research travel fund	Payments for travel and conference fees reimbursed up to £1000/year as part of clinical lectureship
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None Non	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Co-lead of the Maternal and Fetal Adverse Event Terminology Steering Group	Unpaid

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:			8/26/2021			
Your Name: Manuscript Title:			Kasia Maksym			
			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	(nown):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doub." The author's relationships/activitie epidemiology of hypertension, yo that medication is not mentioned.		ipt. "Rela of the man e in doubt os/activition nsion, you entioned all suppo	rt for the work reported in this manuscript without time limit. For all other items, the time			
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present		one			
	manuscript (e.g., funding, provision		an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
	of study materials, medical writing,		tchell Charitable Trust in memory of na Mitchell Glynn	Institutional payments		
	article processing		ees Trust	Institutional payments		
	charges, etc.) No time limit for this item.					
			Time frame: past 36 month	ns		
2	Grants or contracts from any entity (if not indicated in item #1 above).	× No	one			
3	Royalties or licenses	⊠ No	one			

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:		5/30/2023	5/30/2023			
Your Name:		Kurt Hecher	Kurt Hecher			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	nown): 169199-JCI-CMED-RV-2		_		
con affe ind The epi	ntent of your manuscri ected by the content o icate a bias. If you are e author's relationships demiology of hyperter	ot. "Related" means any relation we the manuscript. Disclosure repres in doubt about whether to list a rel	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the a should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.			
	tem #1 below, report a me for disclosure is the		this manuscript wi	thout time limit. For all other items, the time		
		Name all entities with whom you h relationship or indicate none (add		Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since t	he initial planning c	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	□ None European Union Seventh Framewo (FP7/2007-2013) grant agreement	no. 305823	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
	this item.					
		Time fran	ne: past 36 months	;		
2		Time fran ☑ None	ne: past 36 months			

			ecifications/Comments (e.g., if payments were de to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:			6/7/2023			
Your Name:			Francesc Figueras			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	(nown):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doubt." The author's relationships/activities.			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.			
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present	□ No	one			
	manuscript (e.g., funding, provision of study materials,	-	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
	medical writing,			Click the tab key to add additional rows.		
	article processing charges, etc.) No time limit for this item.					
			Time frame: past 36 month	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ No	one			
3	Royalties or licenses	⊠ No	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Roche Diagnostics	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

FRANCESC FIGUERAS RETUERTA - DNI 52197919V

Firmado digitalmente por FRANCESC FIGUERAS RETUERTA - DNI 52197919V Fecha: 2023.06.07 10:11:19 +02'00'

Date:			5/26/2023			
Your Name:			Gareth Ambler			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if l	known):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mar			ated" means any relation with for-profit or no nuscript. Disclosure represents a commitme	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily tabout whether to list a relationship/activity/interest, it is preferable that you do so.		
epi	-	ension, yo		example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
	tem #1 below, report me for disclosure is th		·	ithout time limit. For all other items, the time		
			Il entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
			•			
1	All support for the	□ N	one			
1	present manuscript (e.g., funding, provision	Europe		Chief Investigator Anna David, institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Europe	one ean Union Seventh Framework Programme	Chief Investigator Anna David, institutional		
1	present manuscript (e.g., funding, provision of study materials,	Europe	one ean Union Seventh Framework Programme	Chief Investigator Anna David, institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe	one ean Union Seventh Framework Programme	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month one	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month one	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		

			omments (e.g., if payments were to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None □	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:	5/26/2023
Your Name:	Dr Harry J Whitwell
Manuscript Title:	Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction
Manuscript Number (if known):	169199-JCI-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning	of the work
e 🗆 None	
European Union Seventh Framework Programme (FP7/2007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments
Shoshana Mitchell Glynn	Institutional payments
Rosetrees Trust	Institutional payments
Cancer Research UK PRC Programme Grant A12677	Principle Investigator: John Timms, institutional payments
Eve Appeal Gynaecological Cancer Research Trust through the Predicting Risk of Ovarian Malignancies, Improved Screening and Early detection (PROMISE)	Institutional Payments Click the Instiatab key to add additional rows.
Imperial College London NIHR Biomedical Research Centre	Support for Dr Harry Whitwell
Time frame: past 36 montl	ns
1 6	relationship or indicate none (add rows as needed) Time frame: Since the initial planning None European Union Seventh Framework Programme (FP7/2007-2013) grant agreement no. 305823 The Mitchell Charitable Trust in memory of Shoshana Mitchell Glynn Rosetrees Trust Cancer Research UK PRC Programme Grant A12677 Eve Appeal Gynaecological Cancer Research Trust through the Predicting Risk of Ovarian Malignancies, Improved Screening and Early detection (PROMISE) Imperial College London NIHR Biomedical Research Centre

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
ж	Royalties or licenses	None ■	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board,	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or				
	advocacy group, paid or unpaid				
11	Stock or stock options	\boxtimes	None		
12	Receipt of equipment,	\boxtimes	None		
	materials, drugs, medical writing,				
	gifts or other				
	services				
13	Other financial or non-financial		None		
	interests				
Plea	Please place an "X" next to the following statement to indicate your agreement:				
\square	I certify that I have answered every question and have not altered the wording of any of the questions on this form				

Date:		-	5/26/2023			
Your Name:		_	Nuno Rocha Nene			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at			
			diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	nown):	169199-JCI-CMED-RV-2			
content of your manuscript. "Rela affected by the content of the mai indicate a bias. If you are in doubt			ask you to disclose all relationships/activities/interests listed below that are related to the ted" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.			
-	demiology of hyperter t medication is not me	-		acturers of antihypertensive medication, even if		
	em #1 below, report and the second se			ithout time limit. For all other items, the time		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
			rime trame. Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials	Europea (FP7/20	one an Union Seventh Framework Programme 107-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Europea (FP7/20 Cancer	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 Research UK C12077/A26223) chell Charitable Trust in memory of	Chief Investigator Anna David, institutional		
1	present manuscript (e.g., funding, provision of study materials,	Europea (FP7/20 Cancer The Mit Shoshar	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 Research UK C12077/A26223)	Chief Investigator Anna David, institutional payments Funding for Dr Nuno Rocha Nene Institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Europea (FP7/20 Cancer The Mit Shoshar	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 Research UK C12077/A26223) Inchell Charitable Trust in memory of the Mitchell Glynn	Chief Investigator Anna David, institutional payments Funding for Dr Nuno Rocha Nene		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europea (FP7/20 Cancer The Mit Shoshar	an Union Seventh Framework Programme (07-2013) grant agreement no. 305823 Research UK C12077/A26223) Ichell Charitable Trust in memory of the machine Mitchell Glynn es Trust	Chief Investigator Anna David, institutional payments Funding for Dr Nuno Rocha Nene Institutional payments Institutional payments		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europea (FP7/20 Cancer The Mit Shoshar Rosetre	an Union Seventh Framework Programme 107-2013) grant agreement no. 305823 Research UK C12077/A26223) Inchell Charitable Trust in memory of the Mitchell Glynn	Chief Investigator Anna David, institutional payments Funding for Dr Nuno Rocha Nene Institutional payments Institutional payments		

			cifications/Comments (e.g., if payments were de to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None ■	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form				

Date:			5/25/2023			
Your Name:			Neil SEBIRE			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if	known):	169199-JCI-CMED-RV-2			
content of your manuscript. "Rela affected by the content of the ma			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily tabout whether to list a relationship/activity/interest, it is preferable that you do so.			
epi		ension, you		example, if your manuscript pertains to the facturers of antihypertensive medication, even if		
	tem #1 below, report me for disclosure is th			vithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the		one			
1	present manuscript (e.g., funding, provision	Europe	one an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Europe	an Union Seventh Framework Programme	_		
1	present manuscript (e.g., funding, provision of study materials,	Europe	an Union Seventh Framework Programme	payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Europe	an Union Seventh Framework Programme	payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europe (FP7/20	an Union Seventh Framework Programme	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Europe (FP7/20	Time frame: past 36 month	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Europe (FP7/20	Time frame: past 36 month one	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	Europe (FP7/20	Time frame: past 36 month	Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	Time frame: past 36 month one	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Europe (FP7/20	Time frame: past 36 month one coemdical Research Centre infrastructure C research award	Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	Time frame: past 36 month one coemdical Research Centre infrastructure C research award	Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:			5/26/2023			
Υοι	ır Name:		Stefan R. Hansson			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if	known):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doubt." The author's relationships/activities.			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if			
In i	t medication is not m tem #1 below, report me for disclosure is th	: all suppo	rt for the work reported in this manuscript w	rithout time limit. For all other items, the time		
			ll entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
4						
1	All support for the present		one	Chief Investigator Appa David institutional		
1	present manuscript (e.g., funding, provision	Europe	one ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
1	present manuscript (e.g.,	Europe	ean Union Seventh Framework Programme			
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Europe	ean Union Seventh Framework Programme	payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Europe	ean Union Seventh Framework Programme	payments		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe	ean Union Seventh Framework Programme	payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823	payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Europe (FP7/20	ran Union Seventh Framework Programme 2007-2013) grant agreement no. 305823 Time frame: past 36 month one	payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above). Royalties or	Europe (FP7/20	ran Union Seventh Framework Programme 2007-2013) grant agreement no. 305823 Time frame: past 36 month one	payments Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None None
8	Patents planned, issued or pending	None related to this work
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:			7/8/2023		
You	ır Name:		Anke Diemert		
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction		
Ma	nuscript Number (if	known):	169199-JCI-CMED-RV-2		
content of your manuscript. "Rela affected by the content of the ma			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		ension, you	es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present	□ Ne	one		
	•				
	manuscript (e.g., funding, provision		an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments	
	manuscript (e.g.,		_	_	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing		_	payments	
	manuscript (e.g., funding, provision of study materials, medical writing,		_	payments	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		_	payments Click the tab key to add additional rows.	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	(FP7/20	007-2013) grant agreement no. 305823	payments Click the tab key to add additional rows.	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	(FP7/20	007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	(FP7/20	007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	(FP7/20	007-2013) grant agreement no. 305823 Time frame: past 36 month	payments Click the tab key to add additional rows.	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	(FP7/20	Time frame: past 36 month	payments Click the tab key to add additional rows.	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	(FP7/20	Time frame: past 36 month	payments Click the tab key to add additional rows.	

			or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form			

Date:			6/7/2023			
You	r Name:		Jana Brodszki			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Maı	nuscript Number (if I	known):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doubt			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.			
epic		ension, yo	u should declare all relationships with manufa	acturers of antihypertensive medication, even if		
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time		
			Il entities with whom you have this ship or indicate none (add rows as needed) Time frame: Since the initial planning	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All support for the present	□ N	one	of the work		
	manuscript (e.g., funding, provision of study materials,	-	ean Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments		
	medical writing, article processing			Click the tab key to add additional rows.		
	charges, etc.) No time limit for this item.					
			Time frame: past 36 month	S		
2	Grants or contracts from any entity (if not	⊠ N	one			
indicated in item #1 above).						
3	Royalties or licenses	× N	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comme made to you or to you	nts (e.g., if payments were r institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:			6/5/2023			
Your Name:			Eduard Gratacos			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	nuscript Number (if k	known):	169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activities.			e ask you to disclose all relationships/activities/interests listed below that are related to the sted" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the a should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.			
	em #1 below, report ne for disclosure is th			rithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europe	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europe (FP7/20	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823 Time frame: past 36 month	Payments Click the tab key to add additional rows.		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe (FP7/20	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	payments Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if made to you or to your institution	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				

Date:			6/7/2023		
Your Name:			Yuval Ginsberg		
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction		
Ma	nuscript Number (if k	(nown):	169199-JCI-CMED-RV-2		
content of your manuscript. "Rela affected by the content of the ma			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epi		nsion, yοι	•	example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
In item #1 below, report all suppo frame for disclosure is the past 36				rithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
				made to you or to your mistitution;	
			Time frame: Since the initial planning		
1	All support for the present				
1		□ No	Time frame: Since the initial planning		
1	present manuscript (e.g.,	□ No Europe (FP7/20) The Mit	Time frame: Since the initial planning one an Union Seventh Framework Programme	of the work Chief Investigator Anna David, institutional	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Europe (FP7/20 The Mit Shosha	Time frame: Since the initial planning one an Union Seventh Framework Programme 007-2013) grant agreement no. 305823 tchell Charitable Trust in memory of	of the work Chief Investigator Anna David, institutional payments	
1	present manuscript (e.g., funding, provision of study materials, medical writing,	Europe (FP7/20 The Mit Shosha Rosetre Nationa	Time frame: Since the initial planning one an Union Seventh Framework Programme 007-2013) grant agreement no. 305823 tchell Charitable Trust in memory of na Mitchell Glynn	of the work Chief Investigator Anna David, institutional payments Institutional payments	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe (FP7/20 The Mit Shosha Rosetre Nationa College	Time frame: Since the initial planning one an Union Seventh Framework Programme 207-2013) grant agreement no. 305823 tchell Charitable Trust in memory of na Mitchell Glynn ees Trust	Of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe (FP7/20 The Mit Shosha Rosetre Nationa College Centre	Time frame: Since the initial planning one an Union Seventh Framework Programme 207-2013) grant agreement no. 305823 stchell Charitable Trust in memory of na Mitchell Glynn ees Trust al Institute for Health Research University London Hospitals Biomedical Research	Of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing	

licenses

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:		6/8/2023				
Your Name:		Tal Weissbach	Tal Weissbach			
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction			
Ma	Manuscript Number (if known): 169199-JCI-CMED-RV-2					
cor affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.					
epi			example, if your manuscript pertains to the facturers of antihypertensive medication, even if			
	tem #1 below, report all sume for disclosure is the pas	pport for the work reported in this manuscript vt 36 months.	vithout time limit. For all other items, the time			
		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		-	made to you or to your institution)			
1		cionship or indicate none (add rows as needed)	made to you or to your institution)			
1	All support for the present manuscript (e.g.,	ionship or indicate none (add rows as needed) Time frame: Since the initial planning	made to you or to your institution)			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Time frame: Since the initial planning None Topean Union Seventh Framework Programme	made to you or to your institution) g of the work Chief Investigator Anna David, institutional			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) Ro	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn setrees Trust tional Institute for Health Research University	made to you or to your institution) g of the work Chief Investigator Anna David, institutional payments Institutional payments			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust tional Institute for Health Research University lege London Hospitals Biomedical Research	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust tional Institute for Health Research University lege London Hospitals Biomedical Research	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust tional Institute for Health Research University lege London Hospitals Biomedical Research	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust tional Institute for Health Research University lege London Hospitals Biomedical Research	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing			
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning None Topean Union Seventh Framework Programme 7/2007-2013) grant agreement no. 305823 Mitchell Charitable Trust in memory of oshana Mitchell Glynn Setrees Trust tional Institute for Health Research University lege London Hospitals Biomedical Research Intre Time frame: past 36 mont	made to you or to your institution) of the work Chief Investigator Anna David, institutional payments Institutional payments Institutional payments Access to facilities for sample processing			

40 12/13/2021 ICMJE Disclosure Form

#1 above).

Royalties or

licenses

 \boxtimes

None

3

			cations/Comments (e.g., if payments were o you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	e following statement to indicate your agreeme	

Date:		6/6/2023			
Your Name:		Donald Peebles	Donald Peebles		
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction		
Ma	nuscript Number (if kr	own): 169199-JCI-CMED-RV-2			
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub." The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned.		it. "Related" means any relation with for-profit or the manuscript. Disclosure represents a commitm in doubt about whether to list a relationship/activi /activities/interests should be defined broadly. For sion, you should declare all relationships with man- ntioned in the manuscript.	rt for the work reported in this manuscript without time limit. For all other items, the time		
		Name all entities with whom you have this elationship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial plannin	g of the work		
1	All support for the present manuscript (e.g.,	☐ NoneEuropean Union Seventh Framework Programme	Chief Investigator Anna David, institutional		
	funding, provision	(FP7/2007-2013) grant agreement no. 305823			
	of study materials,		payments		
	medical writing,		Click the tab key to add additional rows.		
	medical writing, article processing charges, etc.) No time limit for this item.				
	charges, etc.) No time limit for	Time frame: past 36 mon	Click the tab key to add additional rows.		
2	charges, etc.) No time limit for	Time frame: past 36 mon ☑ None	Click the tab key to add additional rows.		
2	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item		Click the tab key to add additional rows.		
2	article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item		Click the tab key to add additional rows.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options		None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None		
13	Other financial or non-financial interests		None		
Plea	Please place an "X" next to the following statement to indicate your agreement:				

Date:	5/26/2023
Your Name:	Professor IAN ZACHARY
Manuscript Title:	Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early- onset fetal growth restriction
Manuscript Number (if known):	169199-JCI-CMED-RV-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision	□ None European Union Seventh Framework Programme	Chief Investigator Anna David, institutional
	of study materials,	(FP7/2007-2013) grant agreement no. 305823	payments
	medical writing,		Click the tab key to add additional rows.
	article processing charges, etc.) No time limit for this item.		
		Time frame: past 36 month	ns
2	Grants or contracts from	□ None	
	any entity (if not indicated in item	British Heart Foundation	Principal Investigator, BHF Project Grant no. PG/17/20/32864
	#1 above).	British Heart Foundation	Principal Investigator, supervisor on BHF MBPhD Studentship
		National Institute for Biological Standards and Control (NIBSC)	Co-investigator, supervisor on NIBSC PhD studentship
		Medical Research Council	Co-investigator, MRC DPFS Research Grant MR/V005871/1

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	Allen & Overy LLP and their clients, Regeneron, Inc. and Bayer AG	Paid consultant
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in	⊠ None	

			es with whom you have this indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	⊠ None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement: \[\subseteq I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:			5/26/2023		
Your Name:			Neil Marlow		
Manuscript Title:			Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction		
Maı	nuscript Number (if k	known):	169199-JCI-CMED-RV-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. des/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
	em #1 below, report ne for disclosure is th			ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Europe	an Union Seventh Framework Programme 007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe	an Union Seventh Framework Programme	payments Click the tab key to add additional rows.	
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Europe (FP7/20	Time frame: past 36 month	payments Click the tab key to add additional rows.	

Consulting fees	None	
	□ None	
	InfanDx	Consultancy fees made to me
Payment or	None	
honoraria for lectures, presentations,	Chiesi UK Ltd	2 lecture fees
speakers bureaus, manuscript writing or educational events		
Payment for expert testimony	⊠ None	
Support for attending	□ None	
meetings and/or travel	MCA Events	European Academy of Paediatrics meeting (fees and accommodation)
		Summer Discussions in Provence (fees and accommodation)
Patents planned, issued or	⊠ None	
pending		
Participation on	□ None	
Monitoring Board or	NIHR	Chair Study Steering Committee CF-Start Chair Study Steering Committee Dolfin Study
Leadership or	None	Member DMC Surviving Crying Study
other board,		
committee or advocacy group,		
HI KSKYVEE FE STATE FENE FENE FOR STATE	conoraria for ectures, presentations, peakers pureaus, manuscript virting or educational events. Cayment for expert testimony. Catents planned, expert testimony ending meetings and/or ravel. Catents planned, essued or pending. Carticipation on a Data Safety Monitoring. Cadvisory Board. Cadership or iduciary role in other board, exciety, committee or	Chiesi UK Ltd Chiesi

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			

Date:	5/28/2023 Angela Huertas	
Your Name:		
Manuscript Title:	Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction	
Manuscript Number (if known):	169199-JCI-CMED-RV-2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	European Union Seventh Framework Programme (FP7/2007-2013) grant agreement no. 305823	Chief Investigator Anna David, institutional payments Click the tab key to add additional rows.
		Time frame: past 36 month	ns .
2	Grants or contracts from any entity (if not indicated in item #1 above).	None ■	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement: Certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	5/27/2023
Your Name:	Anna David
Manuscript Title:	Maternal PIGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction
Manuscript Number (if known):	169199-JCI-CMED-RV-2
content of your manuscript. "Rela affected by the content of the mar	e ask you to disclose all relationships/activities/interests listed below that are related to the sted" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if pa made to you or to your institution)		Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None European Union Seventh Framework Programme (FP7/2007-2013) grant agreement no. 305823 The Mitchell Charitable Trust in memory of Shoshana Mitchell Glynn Rosetrees Trust	Chief Investigator Anna David, institutional payments Co-Investigator, Institutional payments Co-Investigator, Institutional payments
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None Medical Research Council Wellcome Leap In Utero	Principal Investigator, institutional payments Co-investigator, institutional payments
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None Non	
8	Patents planned, issued or pending	None Non	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	□ None Tommy's charity	Trustee (unpaid)

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			